HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chew, D. P. Articles by Moliterno, D. J. Search for Related Content PubMed PubMed Citation Articles by Chew, D. P. Articles by Moliterno, D. J.

REVIEW ARTICLE

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition

^a Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Manuscript received December 23, 1999; revised manuscript received May 23, 2000, accepted July 13, 2000.

Reprint requests and correspondence: Dr. David J. Moliterno, Cleveland Clinic Foundation, Department of Cardiology, Desk F25, 9500 Euclid Avenue, Cleveland, Ohio 44195
Molited{at}ccf.org

Despite the success of abciximab in preventing ischemic events after percutaneous coronary interventions, attempts to develop intravenous, small-molecule glycoprotein IIb/IIIa antagonists and diversify the clinical indications for these agents have produced varied results. The 30-day ischemic event reduction in the percutaneous coronary intervention trials has ranged by over three-fold (16% to 56%) and is greater among the acute coronary syndrome trials. The phase III trials exploring the role of oral glycoprotein IIb/IIIa inhibition have been consistently disappointing, with evolving evidence of increased mortality. Mechanisms contributing to these heterogeneous results may include normal variation in platelet or receptor number, differences in receptor activity, interpatient variation in pharmacological dose-response and the possibility of prothrombotic or nonglycoprotein IIb/IIIa effects. Plausibility of "suboptimal" effect is suggested by several recent studies. Trials investigating the role of intravenous small-molecule IIb/IIIa antagonists highlight the importance of effective dosing. The increase in bleeding and mortality observed in the oral glycoprotein IIb/IIIa studies indicate the consequences of suboptimal dosing on safety on one hand, while raising the possibility of important prothrombotic, counterregulatory or other sudden cardiac events. This article will undertake a review of the relevant platelet biology, discuss the mechanisms that may contribute to suboptimal antiplatelet efficacy with these agents and examine insights from the clinical trials supporting these concepts.

Abbreviations and Acronyms   ACS = acute coronary syndrome   CAPTURE = c7E3 FAB Antiplatelet Therapy in Unstable Refractory Angina trial   EPIC = Evaluation of c7E3 for the Prevention of Ischemic Complications trial   EPILOG = Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-term Outcome With Abciximab Glycoprotein IIb/IIIa Blockade   EPISTENT = Evaluation of IIb/IIIa Platelet Inhibitor for Stenting   ESPRIT = Enhanced Suppression of the Platelet Glycoprotein IIb/IIIa Receptor Using Integrelin Therapy trial   EXCITE = Evaluation of Xemilofiban in Controlling Thrombotic Events   GOLD = Au-Assessing Ultegra   IMPACT II = Integrelin to Manage Platelet Aggregation To Combat Coronary Thrombosis-II trial   MI = myocardial infarction   OPUS TIMI 16 = Orbofiban in Patients With Unstable Coronary Syndromes Thrombolysis In Myocardial Infarction 16 trial   PARAGON = Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network trial   PCI = percutaneous coronary intervention   PRISM = Platelet Receptor Inhibition in Ischemic Syndrome Management trial   PRISM-PLUS = Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms trial   RESTORE = Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis trial   SYMPHONY = Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post Acute Coronary Syndromes trial   TARGET = Do Tirofiban And Reopro Give Similar Efficacy Outcomes Trial

This article has been cited by other articles:

				A Khavandi and P R Walker Acute coronary syndrome BMJ, March 31, 2007; 334(7595): 647 - 648. [Full Text] [PDF]

				M W H Behan and R F Storey Antiplatelet therapy in cardiovascular disease Postgrad. Med. J., March 1, 2004; 80(941): 155 - 164. [Abstract] [Full Text] [PDF]

				M. A Crouch, J. M Nappi, and K. I Cheang Glycoprotein IIb/IIIa Receptor Inhibitors in Percutaneous Coronary Intervention and Acute Coronary Syndrome Ann. Pharmacother., June 1, 2003; 37(6): 860 - 875. [Abstract] [Full Text] [PDF]

				R. G. McKay "Ischemia-guided" versus "early invasive" strategies in the management of acute coronary syndrome/non-ST-segment elevation myocardial infarction: The interventionalist's perspective J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 96S - 102S. [Abstract] [Full Text] [PDF]

				H. R. Hellstrom Platelet Glycoprotein IIb/IIIa Inhibitors Circulation, February 11, 2003; 107 (5): e39 - e39. [Full Text] [PDF]

				R. Chun, B. A. Orser, and M. Madan Platelet Glycoprotein IIb/IIIa Inhibitors: Overview and Implications for the Anesthesiologist Anesth. Analg., October 1, 2002; 95(4): 879 - 888. [Full Text] [PDF]

				M. Roffi, D.P. Chew, D. Mukherjee, D.L. Bhatt, J.A. White, D.J. Moliterno, C. Heeschen, C.W. Hamm, M.A. Robbins, N.S. Kleiman, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy Eur. Heart J., September 2, 2002; 23(18): 1441 - 1448. [Abstract] [Full Text] [PDF]

				A. W. Bonz, B. Lengenfelder, J.o. Strotmann, S. Held, O. Turschner, K. Harre, C. Wacker, C. Waller, N. Kochsiek, M. Meesmann, et al. effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial) J. Am. Coll. Cardiol., August 21, 2002; 40(4): 662 - 668. [Abstract] [Full Text] [PDF]

				T. Ichii, H. Koyama, S. Tanaka, A. Shioi, Y. Okuno, S. Otani, and Y. Nishizawa Thrombospondin-1 Mediates Smooth Muscle Cell Proliferation Induced by Interaction With Human Platelets Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1286 - 1292. [Abstract] [Full Text] [PDF]

				S A Harding, N A Boon, and A D Flapan Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three? Heart, July 1, 2002; 88(1): 11 - 14. [Abstract] [Full Text] [PDF]

				J. A. Ambrose and E. E. Martinez A New Paradigm for Plaque Stabilization Circulation, April 23, 2002; 105(16): 2000 - 2004. [Abstract] [Full Text] [PDF]